GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Short Interest

Cantargia AB (FRA:7V3) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cantargia AB's Short Interest

For the Biotechnology subindustry, Cantargia AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantargia AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Short Interest falls into.


Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Short Interest
Comparable Companies
OSTO:LIPUM OSTO:IMMU OSTO:ONCO OSTO:INIT OSTO:ACE XSAT:CURAS OSTO:ALZ OSTO:KDEV OSTO:ISOFOL XSAT:CESSA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
CANTA:Sweden 7V3:Germany
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Website
https://www.cantargia.com
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines